Palisade bio's lead product candidate, pali-2108 demonstrates potent anti-inflammatory effects in ex-vivo study of whole blood samples challenged with pro-inflammatory lipopolysaccharide (lps)

Company on track to commence phase 1 human clinical study of pali-2108 for the treatment of ulcerative colitis (uc) before year end

PALI Ratings Summary

PALI Quant Ranking